4.5 Article

Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder

Journal

PARKINSONISM & RELATED DISORDERS
Volume 27, Issue -, Pages 102-106

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2016.03.006

Keywords

REM sleep behavior disorder; Cognition; Dementia

Funding

  1. Michael J. Fox Foundation for Parkinson's Research (MJFF)
  2. MJFF
  3. Abbvie
  4. Avid Radiopharmaceuticals
  5. Biogen Idec
  6. Bristol-Myers Squibb
  7. Covance
  8. Eli Lilly Co.
  9. F. Hoffman-La Roche, Ltd.
  10. GE Healthcare
  11. Genentech
  12. GlaxoSmithKline
  13. Lundbeck
  14. Merck
  15. MesoScale
  16. Piramal
  17. Pfizer
  18. UCB
  19. NIH [P50 NS053488, AG10124, NS053488, T32MH065218, K23NS080912, K23 N705080912]
  20. Michael J. Fox Foundation for Parkinson's Research
  21. National Institutes of Health
  22. Novartis Pharmaceuticals
  23. Department of Veterans Affairs
  24. Alzheimer's Disease Cooperative Study
  25. University of Pennsylvania for the QUIP
  26. QUIP-RS
  27. GE Medical
  28. TEVA
  29. Acadia
  30. Eli Lilly
  31. Harbor
  32. IMPAX
  33. Merz, Inc.
  34. Navidea
  35. UCB Pharma US World Meds
  36. National Parkinson Foundation
  37. Auspex
  38. Biotie
  39. Civitas
  40. Michael J. Fox Foundation
  41. Fonds de la Recherche en Sante Quebec
  42. Canadian Institute of Health Research
  43. Parkinson Society
  44. Weston-Garfield Foundation
  45. Webster Foundation
  46. Novartis Canada
  47. Teva Neurosciences
  48. German Research Foundation
  49. International Parkinson Foundations
  50. Michael J Fox Foundation
  51. EU
  52. Desitin
  53. GE Health
  54. Mundipharma
  55. UCB- Amy

Ask authors/readers for more resources

Introduction: Cognitive decline is common in Parkinson's disease (PD), and identifying patients at highest risk for it is essential. We aimed to examine the effect of possible REM sleep behavior disorder (pRBD) on rate of cognitive decline in early PD, for both global cognition and in specific cognitive domains. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site, international study of PD patients untreated at enrollment. pRBD was assessed with the REM sleep behavior disorder questionnaire (RBDSQ). Global cognition was assessed at baseline and annually using the Montreal Cognitive Assessment (MoCA) and a cognitive battery. Linear mixed effects models were used to examine the relationship between pRBD (RBDSQ >= 6) and rate of change in cognitive variables. Age, sex, years of education, and baseline motor and cognitive scores were included as covariates. Results: The baseline sample consisted of 423 individuals with PD, mean age 61.7 years and 65.5% male. Data was available on 389, 366, and 196 participants at 1-year, 2-year, and 3-year follow-up respectively. Possible RBD occurred in 108 (25.5%) at baseline. In multivariate analyses, baseline RBD was associated with greater annual rate of decline in MoCA score (beta = -034, 95%CI -0.54, -0.13, p < 0.001), Symbol Digit Modalities Test (beta = -0.69, 95%CI -1.3, -0.09, p = 0.024), and Hopkins Verbal Learning Test Revised, delayed free recall (beta = -0.21, 95%CI -0.41, -0.013, p = 0.037). Conclusions: Possible RBD is common in early PD and predicts future cognitive decline, particularly in attention and memory domains. (C) 2016 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available